Fundamental analysis · SEC EDGAR · TTM through 31/03/2026

Fundamental analysis of Zoetis Inc.

ZTS · NYSE · Pharmaceutical Preparations

Fundamental quality

ATTRACTIVE

81

out of 100

Breakdown by area

I.GrowthEPS: 9.9% · Revenue: 5.2%
53
II.ProfitabilityNet margin: 28% · ROE: 82.6%
95
III.Financial healthFCF: 23.5%
95

Source: SEC EDGAR · TTM through 31/03/2026

Reading the numbers

On average over recent years, earnings per share grew 9.9% a year and revenue advanced 5.2% a year.

On profitability, Zoetis Inc. shows a net margin of 28%, an ROE of 82.6%.

Its financial health shows a free cash flow margin of 23.5%.

Adding up growth, profitability and financial strength, the traffic light gives ZTS a fundamental quality of 81 out of 100. To also know whether it's cheap or expensive, the price is missing: enter it in the tool and you'll get the valuation verdict (P/E against its sector).

The thresholds are general and the system doesn't judge qualitative factors. See the full methodology and use this analysis as a first filter, never as a final decision.

Is Zoetis Inc. cheap or expensive?

That depends on the current price. Look it up, enter it in the tool and get the full valuation verdict (P/E against its sector).

Compute the valuation →
Advertising

Where to buy Zoetis Inc.?

Brokers you can use to invest in U.S. and European stocks.

Compare the brokers →